RELX-INTERNATIONAL
RELX International, a responsible multinational electronic cigarettes company, is continuing its support for the Hashemite Kingdom of Jordan to adopt a more favourable fiscal policy when it comes to the country’s e-cigarette polices and taxes. Should policies and taxes on these products be revised in line with regional markets such as Egypt, Kuwait, Saudi Arabia and the UAE, Jordanian adult smokers, the business environment and government financial reserves will benefit greatly.
According to the Jordan National Stepwise Survey (STEPs) for Noncommunicable Diseases Risk Factors 2019, adult smokers in Jordan smoke an average of 21.3 cigarettes a day [1]. The rate is said to be amongst the highest in the world, with worldwide scientific research linking high tobacco use to a raft of diseases. In contrast, an increasing number of reputed organisations including the UK’s National Health Service (NHS) has said that e-cigarettes are far less harmful than traditional cigarettes, and can actually help smokers reduce or quit smoking altogether [2].
For adult smokers in Jordan, reforming e-cigarette policies and reducing taxes will bring legal access to accessibly priced, premium quality e-cigarette products, which are backed by the latest research & development. Responsible brands will also be able to work closer with their partners to educate adult consumers about the risks and benefits of their products, and restrict access to minors. Consumers can also rest assured that regulated products have been signed off by the Jordanian Food and Drug Administration, which is the sole national competent authority for drug safety & efficacy and food safety & quality.
While e-cigarette products do contain nicotine and so are not completely without risks, the latter is not the main cause of smoking-related diseases according to various regulatory and health organisations including the aforementioned NHS. In fact, a research paper published on the website ‘Tobacco Control’ has stated that the replacement of combustible cigarettes by e-cigarettes use over a 10-year period yields 6.6-million fewer premature deaths, with 86.7-million fewer life years lost in the Optimistic Scenario in the United States alone [3].
Apart from the benefit to adult smokers in the country, broad e-cigarette reforms will benefit the business and investment environment in Jordan. E-cigarette vendors will be attracted to investing in on-ground facilities to better liaise with the market, while the supply chain responsible for the distribution of products could also experience significant growth; traditionally, e-cigarette products are retailed by small- and medium-businesses, and the legalisation of these products with balanced taxation will attract entrepreneurs keen to set up new retail points across the country.
Through these important reforms, Jordanian authorities will also benefit from the collection of tax revenues from legally imported products. In line with this, authorities will be able to clamp down on tax evasion issues associated with illegal market players, while simultaneously working to curtail the spread of inferior and dangerous black-market products, which do not meet the standards and regulations outlined by local and international authorities. This will positively impact the safety of adult smokers who will be able to access licensed and standard-compliant e-cigarette products at an accessible price.
Links:
[1] Jordan National Stepwise Survey (STEPs) for Noncommunicable Diseases Risk Factors 2019
[2] NHS UK - Using e-cigarettes to stop smoking
[3] Tobacco Control – Potential deaths averted in USA by replacing cigarettes with e-cigarettes
Notes to Editors:
About RELX International
Founded in 2019, RELX International is a multinational electronic cigarettes company that markets and sells RELX, The world’s advanced vape brand powered by SuperSmoothTM technology. RELX, Asia’s leading e-cigarette brand, is widening its footprint across the world, and is currently available in 40+ countries such as the UK, France, Italy, Germany, Indonesia, Philippines, Canada, KSA and the UAE. What sets RELX apart from competition is the fact that it has a full ecosystem (such as closed pods, disposables, device, and power bank accessories) that are designed at a cutting-edge research and development center and produced at one of the world’s largest e-cigarette factories. RELX's mission is to make RELX a trusted brand for legal age adult smokers through state-of-the-art products, industry-leading technologies, and scientific advances in collaboration with talented and committed people around the globe. The company has attracted global talents from Uber, Procter & Gamble, Apple, Beats, and L'Oréal. RELX is proud to be listed in Dubai Duty Free, the first duty free channel in the world.
RELX's Social Media
LinkedIn: RELX International
Instagram: @RELXArabia
Facebook: @RELXArabia
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005655/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
